A Phase II, Randomized, Double-Blind, Multicenter, Multinational, Placebo-Controlled, Parallel- Groups Study to Evaluate the Safety and Efficacy of Intramuscular Injections of Allogeneic PLX-PAD Cells for the Treatment of Subjects With Intermittent Claudication (IC)
Latest Information Update: 04 Apr 2023
At a glance
- Drugs Emiplacel (Primary)
- Indications Intermittent claudication; Peripheral arterial disorders
- Focus Therapeutic Use
- Sponsors Pluri; Pluristem Therapeutics
- 13 Mar 2023 ording to a Pluristem Therapeutics media release, Pluristem Therapeutics has changed its name to Pluri Inc.
- 11 Feb 2019 Status changed from active, no longer recruiting to completed.
- 12 Nov 2018 Results presented in a Pluristem Therapeutics Media Release.